Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E21.32 EPS (ttm)10.22 Insider Own0.10% Shs Outstand260.39M Perf Week-2.85%
Market Cap55.80B Forward P/E18.97 EPS next Y11.48 Insider Trans-17.51% Shs Float259.67M Perf Month2.97%
Income2.69B PEG0.84 EPS next Q2.58 Inst Own95.90% Short Float1.12% Perf Quarter-20.00%
Sales5.99B P/S9.31 EPS this Y118.10% Inst Trans-0.30% Short Ratio1.48 Perf Half Y-21.77%
Book/sh31.24 P/B6.97 EPS next Y11.01% ROA27.80% Target Price288.33 Perf Year-0.06%
Cash/sh24.02 P/C9.07 EPS next 5Y25.34% ROE38.20% 52W Range197.47 - 306.08 Perf YTD-0.49%
Dividend- P/FCF18.73 EPS past 5Y28.00% ROI14.70% 52W High-28.82% Beta0.73
Dividend %- Quick Ratio3.60 Sales past 5Y48.30% Gross Margin88.00% 52W Low10.33% ATR7.27
Employees3000 Current Ratio3.70 Sales Q/Q62.00% Oper. Margin44.40% RSI (14)45.02 Volatility2.87% 3.10%
OptionableYes Debt/Eq0.00 EPS Q/Q1060.40% Profit Margin44.90% Rel Volume0.95 Prev Close215.21
ShortableYes LT Debt/Eq0.07 EarningsOct 29 AMC Payout0.00% Avg Volume1.97M Price217.87
Recom2.00 SMA201.19% SMA50-9.00% SMA200-15.31% Volume1,852,049 Change1.24%
Nov-20-20Initiated Bernstein Outperform $225
Oct-28-20Initiated UBS Buy $287
Jul-31-20Reiterated H.C. Wainwright Buy $295 → $315
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $300
Apr-30-20Reiterated H.C. Wainwright Buy $270 → $295
Apr-28-20Downgrade RBC Capital Mkts Outperform → Sector Perform $250 → $260
Mar-04-20Initiated Barclays Overweight $271
Jan-31-20Downgrade Robert W. Baird Outperform → Neutral $210 → $230
Nov-19-19Upgrade Guggenheim Neutral → Buy $252
Nov-12-19Initiated SunTrust Buy $235
Oct-17-19Resumed BofA/Merrill Buy $220
Sep-03-19Upgrade Goldman Neutral → Buy $226 → $254
Aug-01-19Downgrade Needham Buy → Hold
May-23-19Resumed Citigroup Buy $205
May-21-19Initiated Credit Suisse Outperform $209
Apr-12-19Initiated Evercore ISI In-line
Mar-26-19Upgrade William Blair Mkt Perform → Outperform
Mar-19-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19Downgrade Maxim Group Buy → Hold
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Nov-21-20 05:51AM  
Nov-20-20 10:45AM  
09:33AM  
09:32AM  
Nov-15-20 07:04AM  
Nov-13-20 04:01PM  
05:51AM  
Nov-12-20 04:01PM  
06:53AM  
Nov-08-20 11:20PM  
Nov-06-20 06:23AM  
Nov-05-20 04:00AM  
Nov-04-20 04:17PM  
03:16PM  
02:25PM  
02:11PM  
09:15AM  
Nov-01-20 06:57AM  
06:15AM  
Oct-30-20 12:32PM  
06:05AM  
05:01AM  
Oct-29-20 05:35PM  
04:52PM  
04:01PM  
02:30PM  
Oct-28-20 12:55PM  
12:38PM  
07:00AM  
Oct-27-20 11:29AM  
10:08AM  
Oct-26-20 01:06PM  
12:52PM  
09:19AM  
08:45AM  
08:00AM  
08:00AM  
Oct-23-20 07:42AM  
Oct-22-20 01:19PM  
12:34PM  
11:22AM  
Oct-21-20 10:46AM  
09:03AM  
08:55AM  
Oct-20-20 11:30AM  
10:40AM  
09:26AM  
07:39AM  
Oct-19-20 05:50PM  
04:01PM  
Oct-16-20 04:34PM  
01:05PM  
11:16AM  
09:43AM  
07:04AM  
Oct-15-20 07:47PM  
05:44PM  
05:00PM  
04:12PM  
03:12PM  
01:37PM  
12:17PM  
11:54AM  
10:17AM  
09:59AM  
09:51AM  
09:29AM  
08:13AM  
08:03AM  
07:31AM  
04:12AM  
Oct-14-20 06:49PM  
05:19PM  
04:30PM  
12:10PM  
06:06AM  
Oct-13-20 05:50PM  
09:45AM  
Oct-12-20 09:45AM  
Oct-09-20 06:10AM  
Oct-07-20 05:50PM  
10:46AM  
05:51AM  
Oct-06-20 09:01AM  
Oct-04-20 07:32AM  
07:15AM  
06:20AM  
Oct-03-20 07:38AM  
Oct-02-20 05:48AM  
Sep-30-20 11:30AM  
Sep-29-20 05:50PM  
Sep-28-20 12:35PM  
Sep-27-20 05:52AM  
Sep-25-20 08:00AM  
Sep-24-20 05:25AM  
Sep-23-20 11:03AM  
07:07AM  
Sep-22-20 09:00AM  
Sep-21-20 05:50PM  
Sep-18-20 09:32PM  
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sachdev AmitEVP, Chief Patient OfficerNov 16Sale223.53429,38835,103Nov 18 04:16 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffNov 16Sale223.539120,34126,838Nov 18 04:12 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerNov 16Sale223.6471,56535,179Nov 18 04:11 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 16Sale223.47388,49228,902Nov 18 04:10 PM
SACHS BRUCE IDirectorNov 10Buy217.3615,0003,260,46526,210Nov 12 08:18 AM
Parini MichaelEVP, Chief Adm, Leg & BD OffNov 04Option Exercise86.522,330201,59229,168Nov 06 04:09 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffNov 04Sale217.742,330507,32926,838Nov 06 04:09 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerNov 03Option Exercise86.521,553134,36636,732Nov 05 04:16 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerNov 03Sale211.921,553329,11535,179Nov 05 04:16 PM
Bhatia Sangeeta N.DirectorOct 05Option Exercise126.688,7291,105,79014,424Oct 07 04:11 PM
Bhatia Sangeeta N.DirectorOct 05Sale266.7910,5162,805,5183,908Oct 07 04:11 PM
Silva Paul MSVP & ControllerAug 06Option Exercise169.391,078182,59816,010Aug 10 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 06Option Exercise155.571,223190,26230,125Aug 10 04:13 PM
Kewalramani ReshmaCEO & PresidentAug 06Option Exercise179.682,073372,48228,699Aug 10 04:19 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffAug 06Option Exercise155.571,223190,26228,061Aug 10 04:22 PM
Silva Paul MSVP & ControllerAug 06Sale271.171,078292,31914,932Aug 10 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 06Sale271.191,223331,66328,902Aug 10 04:13 PM
Kewalramani ReshmaCEO & PresidentAug 06Sale271.202,073562,20526,626Aug 10 04:19 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffAug 06Sale271.201,223331,67226,838Aug 10 04:22 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Option Exercise86.522,330201,59231,232Aug 05 04:14 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerAug 03Option Exercise86.521,553134,36636,732Aug 05 04:17 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffAug 03Option Exercise86.522,330201,59229,168Aug 05 04:20 PM
Silva Paul MSVP & ControllerAug 03Option Exercise86.5280969,99515,741Aug 05 04:24 PM
Sachdev AmitEVP, Chief Patient OfficerAug 03Option Exercise86.521,941167,93537,044Aug 05 04:51 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Sale278.242,330648,29028,902Aug 05 04:14 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerAug 03Sale278.391,553432,33735,179Aug 05 04:17 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffAug 03Sale278.282,330648,40226,838Aug 05 04:20 PM
Silva Paul MSVP & ControllerAug 03Sale278.30809225,14214,932Aug 05 04:24 PM
Sachdev AmitEVP, Chief Patient OfficerAug 03Sale278.281,941540,13735,103Aug 05 04:51 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffJul 13Option Exercise90.292,125191,86628,963Jul 15 04:41 PM
Silva Paul MSVP & ControllerJul 13Option Exercise90.2986077,64915,792Jul 15 04:51 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffJul 13Sale292.052,125620,61026,838Jul 15 04:41 PM
Silva Paul MSVP & ControllerJul 13Sale292.03860251,14514,932Jul 15 04:51 PM
WAGNER CHARLES F JREVP & Chief Financial OfficerJul 10Sale293.15700205,20616,126Jul 14 04:16 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerJul 07Option Exercise173.512,786483,40337,965Jul 09 04:13 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerJul 07Sale300.002,786835,80035,179Jul 09 04:13 PM
LEIDEN JEFFREY MExecutive ChairmanJun 30Sale286.1532,7929,383,3042,261Jul 02 04:15 PM
Bhatia Sangeeta N.DirectorJun 02Sale282.88952269,2985,695Jun 03 04:22 PM
Kewalramani ReshmaCEO & PresidentMay 15Sale284.179928,13226,626May 19 04:35 PM
Tatsis OuraniaEVP, Chief Regulatory OfficerMay 15Sale284.0012034,08012,738May 19 04:33 PM
Silva Paul MSVP & ControllerMay 15Sale284.0015142,88514,932May 19 04:31 PM
Sachdev AmitEVP, Chief Patient OfficerMay 15Sale284.415816,49635,103May 19 04:29 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 15Sale284.406819,33926,838May 19 04:28 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerMay 15Sale283.9811332,08935,179May 19 04:22 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale284.378223,31828,902May 19 04:21 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 12Option Exercise187.531,304244,53930,206May 14 04:17 PM
LEIDEN JEFFREY MExecutive ChairmanMay 12Option Exercise137.5288,53212,174,639129,353May 14 04:19 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 12Sale287.331,304374,67828,902May 14 04:17 PM
LEIDEN JEFFREY MExecutive ChairmanMay 12Sale283.4794,37026,751,44034,983May 14 04:19 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 11Option Exercise187.531,304244,53928,142May 13 04:18 PM
Sachdev AmitEVP, Chief Patient OfficerMay 11Option Exercise131.8910,6651,406,60745,768May 13 04:20 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 11Sale286.001,304372,94426,838May 13 04:18 PM
Sachdev AmitEVP, Chief Patient OfficerMay 11Sale282.6110,6653,014,01435,103May 13 04:20 PM
LEIDEN JEFFREY MExecutive ChairmanMay 07Option Exercise137.5288,53412,174,982135,190May 08 04:20 PM
SACHS BRUCE IDirectorMay 07Option Exercise70.5545,0003,174,52556,210May 08 04:24 PM
SACHS BRUCE IDirectorMay 07Sale269.8045,00012,140,80611,210May 08 04:24 PM
LEIDEN JEFFREY MExecutive ChairmanMay 07Sale269.7894,36925,459,01340,821May 08 04:20 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 06Option Exercise155.571,222190,10730,124May 08 04:17 PM
Kewalramani ReshmaCEO & PresidentMay 06Option Exercise179.672,074372,63828,700May 08 04:19 PM
Tatsis OuraniaEVP, Chief Regulatory OfficerMay 06Option Exercise174.06966168,14613,704May 08 04:28 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 06Option Exercise155.571,222190,10728,060May 08 04:22 PM
Silva Paul MSVP & ControllerMay 06Option Exercise169.381,076182,25516,008May 08 04:26 PM
Sachdev AmitEVP, Chief Patient OfficerMay 06Option Exercise131.8966988,23435,772May 08 04:23 PM
Silva Paul MSVP & ControllerMay 06Sale272.741,076293,47214,932May 08 04:26 PM
Sachdev AmitEVP, Chief Patient OfficerMay 06Sale275.28669184,16235,103May 08 04:23 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 06Sale272.641,222333,16526,838May 08 04:22 PM
Tatsis OuraniaEVP, Chief Regulatory OfficerMay 06Sale272.70966263,43112,738May 08 04:28 PM
Kewalramani ReshmaCEO & PresidentMay 06Sale272.852,074565,88226,626May 08 04:19 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 06Sale272.661,222333,19528,902May 08 04:17 PM
Sachdev AmitEVP, Chief Patient OfficerMay 05Option Exercise131.8913,3561,761,52348,459May 06 04:43 PM
LEIDEN JEFFREY MExecutive ChairmanMay 05Option Exercise137.5288,53712,175,273141,028May 07 04:24 PM
Sachdev AmitEVP, Chief Patient OfficerMay 05Sale270.0113,3563,606,23235,103May 06 04:43 PM
LEIDEN JEFFREY MExecutive ChairmanMay 05Sale269.9494,37225,475,03746,656May 07 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 04Option Exercise86.522,330201,59231,232May 06 04:17 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 04Option Exercise86.522,330201,59229,168May 06 04:25 PM
Silva Paul MSVP & ControllerMay 04Option Exercise86.5280969,99515,741May 06 04:27 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerMay 04Option Exercise86.521,553134,36636,732May 06 04:38 PM
Sachdev AmitEVP, Chief Patient OfficerMay 04Option Exercise112.9843,7524,942,96878,855May 06 04:43 PM
Sachdev AmitEVP, Chief Patient OfficerMay 04Sale262.2843,75211,475,17935,103May 06 04:43 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerMay 04Sale260.761,553404,95735,179May 06 04:38 PM
Silva Paul MSVP & ControllerMay 04Sale260.87809211,04814,932May 06 04:27 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffMay 04Sale260.872,330607,82726,838May 06 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 04Sale260.862,330607,80328,902May 06 04:17 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffApr 29Option Exercise90.292,125191,86628,963May 01 04:22 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffApr 29Sale254.952,125541,76926,838May 01 04:22 PM
Lee YuchunDirectorApr 28Option Exercise57.271,12564,4293,000Apr 29 04:14 PM
Lee YuchunDirectorApr 28Sale257.881,125290,1151,875Apr 29 04:14 PM
Lee YuchunDirectorApr 27Option Exercise57.272,000114,5403,875Apr 28 04:23 PM
Lee YuchunDirectorApr 27Sale271.212,000542,4191,875Apr 28 04:23 PM
Lee YuchunDirectorApr 24Option Exercise57.272,000114,5403,875Apr 28 04:23 PM
Lee YuchunDirectorApr 24Sale268.142,000536,2861,875Apr 28 04:23 PM
Lee YuchunDirectorApr 23Option Exercise57.272,000114,5403,875Apr 24 04:17 PM
Lee YuchunDirectorApr 23Sale272.532,000545,0521,875Apr 24 04:17 PM
Lee YuchunDirectorApr 22Option Exercise57.272,000114,5403,875Apr 24 04:17 PM
Lee YuchunDirectorApr 22Sale267.882,000535,7531,875Apr 24 04:17 PM
Lee YuchunDirectorApr 21Option Exercise57.272,000114,5403,875Apr 22 04:14 PM
Lee YuchunDirectorApr 21Sale266.762,000533,5231,875Apr 22 04:14 PM
Lee YuchunDirectorApr 20Option Exercise57.272,000114,5403,875Apr 22 04:14 PM
Lee YuchunDirectorApr 20Sale273.162,000546,3101,875Apr 22 04:14 PM
Silva Paul MSVP & ControllerApr 13Option Exercise90.2985977,55915,791Apr 15 04:15 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.